<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696252</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-901800</org_study_id>
    <nct_id>NCT02696252</nct_id>
  </id_info>
  <brief_title>G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator</brief_title>
  <official_title>Comparison of G5® Mobile Continuous Glucose Monitoring System Accuracy When Using an Automated Applicator vs. a Manual Sensor Applicator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DexCom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of G5® Mobile Continuous Glucose Monitoring System Accuracy When Using an&#xD;
      Automated Applicator vs. a Manual Sensor Applicator&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to demonstrate the performance, i.e. efficacy of the G5x System&#xD;
      with the automated applicator is no worse than that of the commercial Dexcom G4 TM PLATINUM&#xD;
      Continuous Glucose Monitoring System (G4 System) with the manual applicator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CGM Users</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults and pediatrics with diabetes mellitus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 2 or older&#xD;
&#xD;
          -  Diagnosis of Type 1 diabetes or Type 2 diabetes&#xD;
&#xD;
          -  Willing to participate in a clinic session involving venous sampling for evaluation of&#xD;
             study end point&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of acetaminophen&#xD;
&#xD;
          -  Known allergy to medical-grade adhesives&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hematocrit outside specification of the study-assigned blood glucose meter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

